Allergan Files Suits Against Imprimis Pharmaceuticals, Prescriber’s Choice, and Sincerus Florida

Source: Allergan

Allergan USA has filed lawsuits against Imprimis Pharmaceuticals, Prescriber's Choice, and Sincerus Florida, alleging that those companies are unlawfully manufacturing and selling unapproved new drugs and violating the Lanham Act and state law by engaging in false and misleading advertising and promotion of their unapproved new drugs, according to a company news release. The suits have been filed in the United States District Court for the Central District of California.

Commenting on the lawsuits, the company issued the following statement:

"Biopharmaceutical companies like Allergan have a duty to put the safety of their patients first. This commitment is the cornerstone of our manufacturing, marketing and advertising of our FDA-approved products. Today, we have brought suit against companies that we believe stand in stark contrast to that commitment. Imprimis Pharmaceuticals, Inc., Prescriber's Choice, Inc., and Sincerus Florida, LLC do not follow the established compounding regulations, engage in false and misleading advertising, and ultimately, put patients and physicians at risk by selling unapproved new drugs."

Related Content